Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Dr Nikolai Dyrberg (University of Copenhagen, Denmark) presented the findings of a Danish nationwide study that followed 1,684 patients with psoriasis receiving biologic therapy for the first time [1]. Median response time was 112 days. At baseline, 746 participants had a PASI of 0; 485 had a PASI between 0 and ≤2; 246 had a PASI >2 but ≤4; and 207 had a PASI >4. Defining a flare-up as any increase of their PASI score by ≥3, 42.8% of patients experienced flare-ups. However, patients with a lower PASI score during the first 6 months of treatment experienced longer flare-free periods. These outcomes were independent of drug, sex, age, weight, and use of methotrexate.
Dr Dyrberg’s team documented a more stable disease course, lower risk of flares, and decreased treatment discontinuation in bio-naïve patients with psoriasis treated with biologics who had a low early PASI response. Given these results, they recommend a treatment target of PASI ≤2 in the first year of treatment in this patient group.
- Dyrberg Loft N. Risk of disease flares during first biologic therapy among patients with stable and controlled psoriasis: A Danish Nationwide Study. P1331, EADV Virtual Congres, 29-31 October 2020.
Posted on
Previous Article
« Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria Next Article
Oral prevention of skin cancer »
« Discontinuation of omalizumab during COVID-19 pandemic associated with poor outcomes for chronic spontaneous urticaria Next Article
Oral prevention of skin cancer »
Related Articles
November 2, 2020
Impact of personal protective equipment on acne vulgaris and rosacea
September 26, 2022
dit is mijn titel
December 23, 2022
Article Title Here In Title Case
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy